{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:05:24Z","timestamp":1794380724620,"version":"4.9.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Progressive supranuclear palsy (PSP) is a pure tauopathy, implicating davunetide, enhancing Tau-microtubule interaction, as an ideal drug candidate. However, pooling patient data irrespective of sex concluded no efficacy. Here, analyzing sex-dependency in a 52 week-long- PSP clinical trial (involving over 200 patients) demonstrated clear baseline differences in brain ventricular volumes, a secondary endpoint. Dramatic baseline ventricular volume-dependent\/volume increase correlations were observed in 52-week-placebo-treated females (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.74,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20092.36\n                    <jats:sup>\u20139<\/jats:sup>\n                    ), whereas davunetide-treated females (like males) revealed no such effects. Assessment of primary endpoints, by the PSP Rating Scale (PSPRS) and markedly more so by the Schwab and England Activities of Daily Living (SEADL) scale, showed significantly faster deterioration in females, starting at trial week 13 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01, and correlating with most other endpoints by week 52). Twice daily davunetide treatments slowed female disease progression and revealed significant protection according to the SEADL scale as early as at 39 weeks (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008), as well as protection of the bulbar and limb motor domains considered by the PSPRS, including speaking and swallowing difficulties caused by brain damage, and deterioration of fine motor skills, respectably (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01), at 52 weeks. Furthermore, at 52 weeks of trial, the exploratory Geriatric Depression Scale (GDS) significantly correlated with the SEADL scale deterioration in the female placebo group and demonstrated davunetide-mediated protection of females. Female-specific davunetide-mediated protection of ventricular volume corresponded to clinical efficacy. Together with the significantly slower disease progression seen in men, the results reveal sex-based drug efficacy differences, demonstrating the neuroprotective and disease-modifying impact of davunetide treatment for female PSP patients.\n                  <\/jats:p>","DOI":"10.1038\/s41398-023-02618-9","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:03:58Z","timestamp":1697443438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-2430","authenticated-orcid":false,"given":"Illana","family":"Gozes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-4955","authenticated-orcid":false,"given":"Guy","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lobyntseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2618_CR1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1471-4159.1999.0721283.x","volume":"72","author":"M Bassan","year":"1999","unstructured":"Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999;72:1283\u201393.","journal-title":"J Neurochem"},{"key":"2618_CR2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/mp.2015.208","volume":"21","author":"N Amram","year":"2016","unstructured":"Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, et al. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol Psychiatry. 2016;21:1467\u201376.","journal-title":"Mol Psychiatry"},{"key":"2618_CR3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41380-019-0563-5","volume":"26","author":"Y Ivashko-Pachima","year":"2021","unstructured":"Ivashko-Pachima Y, Hadar A, Grigg I, Korenkova V, Kapitansky O, Karmon G, et al. Discovery of autism\/intellectual disability somatic mutations in Alzheimer\u2019s brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol Psychiatry. 2021;26:1619\u201333.","journal-title":"Mol Psychiatry"},{"key":"2618_CR4","doi-asserted-by":"crossref","first-page":"e0213666","DOI":"10.1371\/journal.pone.0213666","volume":"14","author":"Y Ivashko-Pachima","year":"2019","unstructured":"Ivashko-Pachima Y, Maor-Nof M, Gozes I. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLoS ONE. 2019;14:e0213666.","journal-title":"PLoS ONE"},{"key":"2618_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biopsych.2021.09.018","volume":"92","author":"G Karmon","year":"2022","unstructured":"Karmon G, Sragovich S, Hacohen-Kleiman G, Ben-Horin-Hazak I, Kasparek P, Schuster B, et al. Novel ADNP syndrome mice reveal dramatic sex-specific peripheral gene expression with brain synaptic and Tau pathologies. Biol Psychiatry. 2022;92:81\u201395.","journal-title":"Biol Psychiatry"},{"key":"2618_CR6","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1038\/s41380-022-01603-w","volume":"27","author":"Y Ivashko-Pachima","year":"2022","unstructured":"Ivashko-Pachima Y, Ganaiem M, Ben-Horin-Hazak I, Lobyntseva A, Bellaiche N, Fischer I, et al. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. Mol Psychiatry. 2022;27:3316\u201327.","journal-title":"Mol Psychiatry"},{"key":"2618_CR7","volume":"11","author":"X Sun","year":"2020","unstructured":"Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt\/beta-catenin signaling. Nat Commun. 2020;11:2984.","journal-title":"Nat Commun"},{"key":"2618_CR8","doi-asserted-by":"crossref","unstructured":"Gozes I, Shazman S. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome. Eur J Neurosci. 2023;58:2641\u201352.","DOI":"10.1111\/ejn.15920"},{"key":"2618_CR9","doi-asserted-by":"crossref","unstructured":"Fraser PE, Yu G, Levesque L, Nishimura M, Yang DS, Mount HT, et al. Presenilin function: connections to Alzheimer\u2019s disease and signal transduction. Biochem Soc Symp. 2001; 89\u2013100.","DOI":"10.1042\/bss0670089"},{"key":"2618_CR10","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-00904-4","volume":"10","author":"I Grigg","year":"2020","unstructured":"Grigg I, Ivashko-Pachima Y, Hait TA, Korenkova V, Touloumi O, Lagoudaki R, et al. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Transl Psychiatry. 2020;10:228.","journal-title":"Transl Psychiatry"},{"key":"2618_CR11","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1172\/JCI98199","volume":"128","author":"G Hacohen-Kleiman","year":"2018","unstructured":"Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, et al. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. J Clin Investig. 2018;128:4956\u201369.","journal-title":"J Clin Investig"},{"key":"2618_CR12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/mp.2014.97","volume":"19","author":"S Oz","year":"2014","unstructured":"Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry. 2014;19:1115\u201324.","journal-title":"Mol Psychiatry"},{"key":"2618_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.138","volume":"5","author":"A Malishkevich","year":"2015","unstructured":"Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer\u2019s pathologies. Transl Psychiatry. 2015;5:e501.","journal-title":"Transl Psychiatry"},{"key":"2618_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.expneurol.2017.11.001","volume":"300","author":"JP Dolle","year":"2018","unstructured":"Dolle JP, Jaye A, Anderson SA, Ahmadzadeh H, Shenoy VB, Smith DH. Newfound sex differences in axonal structure underlie differential outcomes from in vitro traumatic axonal injury. Exp Neurol. 2018;300:121\u201334.","journal-title":"Exp Neurol"},{"key":"2618_CR15","doi-asserted-by":"crossref","first-page":"608444","DOI":"10.3389\/fneur.2020.608444","volume":"11","author":"I Gozes","year":"2020","unstructured":"Gozes I. The ADNP syndrome and CP201 (NAP) potential and hope. Front Neurol. 2020;11:608444.","journal-title":"Front Neurol"},{"key":"2618_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2011.11.001","volume":"136","author":"DC Javitt","year":"2012","unstructured":"Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012;136:25\u201331.","journal-title":"Schizophr Res"},{"key":"2618_CR17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.107.129551","volume":"323","author":"I Vulih-Shultzman","year":"2007","unstructured":"Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323:438\u201349.","journal-title":"J Pharmacol Exp Ther"},{"key":"2618_CR18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1385\/JMN\/31:02:165","volume":"31","author":"Y Matsuoka","year":"2007","unstructured":"Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer\u2019s disease at early pathological stage. J Mol Neurosci. 2007;31:165\u201370.","journal-title":"J Mol Neurosci"},{"key":"2618_CR19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","volume":"325","author":"Y Matsuoka","year":"2008","unstructured":"Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer\u2019s disease. J Pharmacol Exp Ther. 2008;325:146\u201353.","journal-title":"J Pharmacol Exp Ther"},{"key":"2618_CR20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.STR.0000014207.05597.D7","volume":"33","author":"RR Leker","year":"2002","unstructured":"Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke. 2002;33:1085\u201392.","journal-title":"Stroke"},{"key":"2618_CR21","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.4161\/15548627.2014.984274","volume":"10","author":"A Merenlender-Wagner","year":"2014","unstructured":"Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, et al. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy. 2014;10:2324\u201332.","journal-title":"Autophagy"},{"key":"2618_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbadis.2013.10.003","volume":"1842","author":"AR Esteves","year":"2014","unstructured":"Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson\u2019s disease. Biochim Biophys Acta. 2014;1842:7\u201321.","journal-title":"Biochim Biophys Acta"},{"key":"2618_CR23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/mp.2013.174","volume":"20","author":"A Merenlender-Wagner","year":"2015","unstructured":"Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2015;20:126\u201332.","journal-title":"Mol Psychiatry"},{"key":"2618_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1515\/hsz-2015-0152","volume":"397","author":"I Gozes","year":"2016","unstructured":"Gozes I. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Biol Chem. 2016;397:177\u201384.","journal-title":"Biol Chem"},{"key":"2618_CR25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jnr.23808","volume":"95","author":"I Gozes","year":"2017","unstructured":"Gozes I. Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer\u2019s disease. J Neurosci Res. 2017;95:652\u201360.","journal-title":"J Neurosci Res"},{"key":"2618_CR26","doi-asserted-by":"publisher","unstructured":"Sragovich S, Merenlender-Wagner A, Gozes I. ADNP plays a key role in autophagy: from autism to schizophrenia and Alzheimer\u2019s disease. Bioessays. 2017. https:\/\/doi.org\/10.1002\/bies.201700054.","DOI":"10.1002\/bies.201700054"},{"key":"2618_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.nbd.2013.04.012","volume":"56","author":"Y Jouroukhin","year":"2013","unstructured":"Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis. 2013;56:79\u201394.","journal-title":"Neurobiol Dis"},{"key":"2618_CR28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 2014;13:676\u201385.","journal-title":"Lancet Neurol"},{"key":"2618_CR29","first-page":"319","volume":"1","author":"EJ Calabrese","year":"2003","unstructured":"Calabrese EJ. The maturing of hormesis as a credible dose-response model. Nonlinearity Biol Toxicol Med. 2003;1:319\u201343.","journal-title":"Nonlinearity Biol Toxicol Med"},{"key":"2618_CR30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/156720509789207895","volume":"6","author":"I Gozes","year":"2009","unstructured":"Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer\u2019s disease tangles: from NAP to AL-108. Curr Alzheimer Res. 2009;6:455\u201360.","journal-title":"Curr Alzheimer Res"},{"key":"2618_CR31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","volume":"35","author":"BH Morimoto","year":"2013","unstructured":"Morimoto BH, Schmechel D, Hirman J, Blackwell A, Keith J, Gold M, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35:325\u201336.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2618_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00401-021-02392-2","volume":"143","author":"KR Bowles","year":"2022","unstructured":"Bowles KR, Pugh DA, Oja LM, Jadow BM, Farrell K, Whitney K, et al. Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD. Acta Neuropathol. 2022;143:225\u201343.","journal-title":"Acta Neuropathol"},{"key":"2618_CR33","doi-asserted-by":"crossref","first-page":"e87383","DOI":"10.1371\/journal.pone.0087383","volume":"9","author":"Y Schirer","year":"2014","unstructured":"Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. PLoS ONE. 2014;9:e87383.","journal-title":"PLoS ONE"},{"key":"2618_CR34","doi-asserted-by":"crossref","unstructured":"Elhasnaoui J, Ferrero G, Miano V, Cutrupi S, De Bortoli M. The estrogen receptor alpha signaling pathway controls alternative splicing in the absence of ligands in breast cancer cells. Cancers 2021;13:6261.","DOI":"10.3390\/cancers13246261"},{"key":"2618_CR35","doi-asserted-by":"crossref","first-page":"eabm5029","DOI":"10.1126\/sciadv.abm5029","volume":"8","author":"K Tsujikawa","year":"2022","unstructured":"Tsujikawa K, Hamanaka K, Riku Y, Hattori Y, Hara N, Iguchi Y, et al. Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Sci Adv. 2022;8:eabm5029.","journal-title":"Sci Adv"},{"key":"2618_CR36","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.0736237100","volume":"100","author":"CJ Loy","year":"2003","unstructured":"Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA. 2003;100:4562\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2618_CR37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13760-021-01599-0","volume":"122","author":"RR Mahale","year":"2022","unstructured":"Mahale RR, Krishnan S, Divya KP, Jisha VT, Kishore A. Gender differences in progressive supranuclear palsy. Acta Neurol Belg. 2022;122:357\u201362.","journal-title":"Acta Neurol Belg"},{"key":"2618_CR38","doi-asserted-by":"publisher","unstructured":"Bennison SA, Blazejewski SM, Liu X, Hacohen-Kleiman G, Sragovich S, Zoidou S, et al. The cytoplasmic localization of ADNP through 14-3-3 promotes sex-dependent neuronal morphogenesis, cortical connectivity, and calcium signaling. Mol Psychiatry. 2023. https:\/\/doi.org\/10.1038\/s41380-022-01939-3.","DOI":"10.1038\/s41380-022-01939-3"},{"key":"2618_CR39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neulet.2004.09.077","volume":"373","author":"S Furman","year":"2005","unstructured":"Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett. 2005;373:73\u20138.","journal-title":"Neurosci Lett"},{"key":"2618_CR40","doi-asserted-by":"crossref","unstructured":"Kapitansky O, Karmon G, Sragovich S, Hadar A, Shahoha M, Jaljuli I, et al. Single cell ADNP predictive of human muscle disorders: mouse knockdown results in muscle wasting. Cells. 2020;9:2320.","DOI":"10.3390\/cells9102320"},{"key":"2618_CR41","doi-asserted-by":"crossref","unstructured":"Coughlan GT, Betthauser TJ, Boyle R, Koscik RL, Klinger HM, Chibnik LB, et al. Association of age at menopause and hormone therapy use with tau and beta-amyloid positron emission tomography. JAMA Neurol. 2023;80:462\u201373.","DOI":"10.1001\/jamaneurol.2023.0455"},{"key":"2618_CR42","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/brain\/awm021","volume":"130","author":"JL Whitwell","year":"2007","unstructured":"Whitwell JL, Jack CR Jr., Parisi JE, Knopman DS, Boeve BF, Petersen RC, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain. 2007;130:1148\u201358.","journal-title":"Brain"},{"key":"2618_CR43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.24052","volume":"75","author":"CS Scherling","year":"2014","unstructured":"Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116\u201326.","journal-title":"Ann Neurol"},{"key":"2618_CR44","unstructured":"rstatix: Pipe-friendly framework for basic statistical tests. R package version 0.7.2. 2023. https:\/\/rpkgs.datanovia.com\/rstatix\/."},{"key":"2618_CR45","first-page":"987","volume":"3","author":"MAA Omer","year":"2014","unstructured":"Omer MAA, Alasar EMM M, G-eME, Sakin GAE, Bushara YM. Measurement of cranial and brain ventricle volumes relative to pathologies. Int J Sci Res. 2014;3:987\u201391.","journal-title":"Int J Sci Res"},{"key":"2618_CR46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2011.06.020","volume":"44","author":"A Idan-Feldman","year":"2011","unstructured":"Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis. 2011;44:327\u201339.","journal-title":"Neurobiol Dis"},{"key":"2618_CR47","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90:e273\u201381.","journal-title":"Neurology"},{"key":"2618_CR48","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1093\/brain\/awaa327","volume":"143","author":"R Smith","year":"2020","unstructured":"Smith R, Strandberg O, Mattsson-Carlgren N, Leuzy A, Palmqvist S, Pontecorvo MJ, et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain. 2020;143:3805\u201315.","journal-title":"Brain"},{"key":"2618_CR49","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.26694","volume":"31","author":"S Hewer","year":"2016","unstructured":"Hewer S, Varley S, Boxer AL, Paul E, Williams DR, Investigators AL. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Mov Disord. 2016;31:1574\u20137.","journal-title":"Mov Disord"},{"key":"2618_CR50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1523\/JNEUROSCI.2305-16.2016","volume":"37","author":"V Lacovich","year":"2017","unstructured":"Lacovich V, Espindola SL, Alloatti M, Pozo Devoto V, Cromberg LE, Carna ME, et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J Neurosci. 2017;37:58\u201369.","journal-title":"J Neurosci"},{"key":"2618_CR51","volume":"9","author":"S Sragovich","year":"2019","unstructured":"Sragovich S, Malishkevich A, Piontkewitz Y, Giladi E, Touloumi O, Lagoudaki R, et al. The autism\/neuroprotection-linked ADNP\/NAP regulate the excitatory glutamatergic synapse. Transl Psychiatry. 2019;9:2.","journal-title":"Transl Psychiatry"},{"key":"2618_CR52","doi-asserted-by":"crossref","first-page":"e0253079","DOI":"10.1371\/journal.pone.0253079","volume":"16","author":"Y Takamatsu","year":"2021","unstructured":"Takamatsu Y, Aiba I. Skeletal muscle loss and body composition in progressive supranuclear palsy: a retrospective cross-sectional study. PLoS ONE. 2021;16:e0253079.","journal-title":"PLoS ONE"},{"key":"2618_CR53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","volume":"115","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson\u2019s disease, PSP and MSA. J Neural Transm. 2008;115:1001\u20139.","journal-title":"J Neural Transm"},{"key":"2618_CR54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11307-012-0556-0","volume":"14","author":"DM van Assema","year":"2012","unstructured":"van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al. P-glycoprotein function at the blood-brain barrier: effects of age and gender. Mol Imaging Biol. 2012;14:771\u20136.","journal-title":"Mol Imaging Biol"},{"key":"2618_CR55","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/brain\/awn146","volume":"131","author":"SM Nestor","year":"2008","unstructured":"Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer\u2019s disease progression validated using the Alzheimer\u2019s disease neuroimaging initiative database. Brain. 2008;131:2443\u201354.","journal-title":"Brain"},{"key":"2618_CR56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41582-022-00660-7","volume":"18","author":"S Ayton","year":"2022","unstructured":"Ayton S. Ventricular enlargement caused by aducanumab. Nat Rev Neurol. 2022;18:383\u20134.","journal-title":"Nat Rev Neurol"},{"key":"2618_CR57","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1111\/febs.15656","volume":"288","author":"G Richter","year":"2021","unstructured":"Richter G, Gui T, Bourgeois B, Koyani CN, Ulz P, Heitzer E, et al. beta-catenin regulates FOXP2 transcriptional activity via multiple binding sites. FEBS J. 2021;288:3261\u201384.","journal-title":"FEBS J"},{"key":"2618_CR58","doi-asserted-by":"crossref","unstructured":"Kapitansky O, Sragovich S, Jaljuli I, Hadar A, Giladi E, Gozes I. Age and sex-dependent ADNP regulation of muscle gene expression is correlated with motor behavior: possible feedback mechanism with PACAP. Int J Mol Sci. 2020;21:6715.","DOI":"10.3390\/ijms21186715"},{"key":"2618_CR59","doi-asserted-by":"crossref","DOI":"10.1038\/srep16300","volume":"5","author":"S Vaisburd","year":"2015","unstructured":"Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Sci Rep. 2015;5:16300.","journal-title":"Sci Rep"},{"key":"2618_CR60","doi-asserted-by":"crossref","first-page":"920352","DOI":"10.3389\/fnagi.2022.920352","volume":"14","author":"M Yang","year":"2022","unstructured":"Yang M, Cui Y, Xue M, Forster MT, Lang X, Xiu M, et al. Sexual dimorphism in the relationship between Forkhead-Box P2 and BMI with cognitive deficits in schizophrenia. Front Aging Neurosci. 2022;14:920352.","journal-title":"Front Aging Neurosci"},{"key":"2618_CR61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/npp.2013.23","volume":"38","author":"LF Jarskog","year":"2013","unstructured":"Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013;38:1245\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"2618_CR62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2022.03.011","volume":"92","author":"H Amal","year":"2022","unstructured":"Amal H. Sex and the brain: novel ADNP syndrome mice are protected by NAP. Biol Psychiatry. 2022;92:8\u20139.","journal-title":"Biol Psychiatry"},{"key":"2618_CR63","doi-asserted-by":"crossref","first-page":"eade0764","DOI":"10.1126\/sciadv.ade0764","volume":"8","author":"H Yang","year":"2022","unstructured":"Yang H, Oh CK, Amal H, Wishnok JS, Lewis S, Schahrer E, et al. Mechanistic insight into female predominance in Alzheimer\u2019s disease based on aberrant protein S-nitrosylation of C3. Sci Adv. 2022;8:eade0764.","journal-title":"Sci Adv"},{"key":"2618_CR64","doi-asserted-by":"publisher","unstructured":"Shulman D, Dubnov S, Zorbaz T, Madrer N, Paldor I, Bennett DA, et al. Sex-specific declines in cholinergic-targeting tRNA fragments in the nucleus accumbens in Alzheimer\u2019s disease. Alzheimers Dement. 2023. https:\/\/doi.org\/10.1002\/alz.13095.","DOI":"10.1002\/alz.13095"},{"key":"2618_CR65","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/mds.29419","volume":"38","author":"TF Outeiro","year":"2023","unstructured":"Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, et al. Defining the riddle in order to solve it: there is more than one \u201cParkinson\u2019s disease\u201d. Mov Disord. 2023;38:1127\u201342.","journal-title":"Mov Disord"},{"key":"2618_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13293-020-00310-x","volume":"11","author":"EE Sundermann","year":"2020","unstructured":"Sundermann EE, Panizzon MS, Chen X, Andrews M, Galasko D, Banks SJ, et al. Sex differences in Alzheimer\u2019s-related Tau biomarkers and a mediating effect of testosterone. Biol Sex Differ. 2020;11:33.","journal-title":"Biol Sex Differ"},{"key":"2618_CR67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neurobiolaging.2021.03.010","volume":"105","author":"YV Doust","year":"2021","unstructured":"Doust YV, King AE, Ziebell JM. Implications for microglial sex differences in tau-related neurodegenerative diseases. Neurobiol Aging. 2021;105:340\u20138.","journal-title":"Neurobiol Aging"},{"key":"2618_CR68","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fnins.2020.00893","volume":"14","author":"P Alster","year":"2020","unstructured":"Alster P, Madetko N, Koziorowski D, Friedman A. Microglial activation and inflammation as a factor in the pathogenesis of progressive supranuclear palsy (PSP). Front Neurosci. 2020;14:893.","journal-title":"Front Neurosci"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02618-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:09:19Z","timestamp":1700536159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02618-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"9 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sex-dependent use of davunetide for PSP and other conditions is under international patent application No. PCT PCT\/IL2022\/051314 (all authors are listed as inventors).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}